<DOC>
	<DOCNO>NCT02767063</DOCNO>
	<brief_summary>Patients randomize phase II trial continue TKI versus one alternative treatment approach . If patient eligible one treatment , ( ) randomize option ( ) eligible . The trial start current available treatment option ( experimental arm ) . New available treatment option may open time later . Authorized TKIs imatinib , nilotinib , dasatinib , bosutinib ponatinib . For option treatment duration minimum 12 month continue absence adverse event follow investigator decision . Each therapeutic option detailed term combination modality , dose , dose adaptation , specific warning , specific exclusion inclusion criterion . The decision introduce new option depend general pace recruitment assessment potential efficacy safety new treatment , implement scientific review protocol amendment . Primary objective : A . To select molecule combination sequentially imatinib , nilotinib , dasatinib , bosutinib ponatinib potentially able produce 25 % increase Cumulative Incidence MR4.5 compare control . Secondary objective : A . To determine safety select therapy B . To determine rate MR4 12 , 24 , 36 , 48 month experimental control arm C. To determine rate MR4.5 24 , 36 , 48 month experimental control arm D. To determine rate undetectable BCR-ABL1 transcript ( sensitivity 40000 ABL copy ) 12 , 24 , 36 , 48 month experimental control arm E. To estimate treatment free remission ( TFR ) patient eligible discontinuation study F. To investigate relationship biological activity clinical efficacy select therapy G. To assess effect treatment number clonogenicity CML stem cell biological marker interest H. To estimate duration response , progression-free survival , event free survival overall survival .</brief_summary>
	<brief_title>Therapies Combination Sequentially With Tyrosine Kinase Inhibitors ( TKIs ) Chronic Phase Chronic Myelogenous Leukemia Patients CCR ( ACTIW )</brief_title>
	<detailed_description>Patients randomise continue TKI ( daily dose ) versus one X alternative novel treatment approach . If patient eligible one treatment , randomise option eligible . All treatment option may open time . The first available treatment arm : 1 . TKI alone daily dose ( control arm ) 2 . TKI combination pioglitazone Planned treatment arm future may : 1 . TKI combination pegylated interferon 2 . TKI combination arsenic trioxide 3 . TKI combination Homoharringtonine 4 . TKI combination anti-PD-L1 antibody For option treatment plan least 12 month depend molecule test . New treatment option introduce time . The decision introduce new option depend general pace recruitment assessment potential efficacy safety new treatment patient population , implement scientific review protocol amendment . Protocol plan : 1 . Control arm ( Imatinib , nilotinib , dasatinib , bosutinib ponatinib ) : Daily dose schedule identical daily dose schedule administer last 3 month 2 . Pioglitazone arm TKI : Daily dose schedule identical daily dose schedule administer last 3 month PIOGLITAZONE ( Actos® ) : 30 mg per day 12 month . The dose increase 45 mg per day 2 month absence grade &gt; 1 related AE . 3 . Other experimental arm TKI : Daily dose schedule identical daily dose schedule administer last 3 month - Arsenic trioxide : determine amendment - Pegylated Interferon : determine amendment - Anti-PD-L1 antibody : determine amendment - Homoharringtonine : determine amendment - Drug X - Drug Y After 12 Months : Continue TKI daily dose . Continue experimental drug indicate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Patient age 18y 2 . Signed informed consent 3 . Patient Philadelphia chromosome positive chronic phase CML M BCRABL1 transcript positivity 4 . Treatment imatinib , nilotinib , dasatinib , bosutinib ponatinib 2 year overall 5 . No switch tyrosine kinase inhibitor within last 3 month 6 . No dose modification within last 3 month 7 . Complete cytogenetic response BCRABLIS ≤ 1 % 8 . Detectable BCRABL1 BCRABLIS &gt; 0.0032 % ( less MR4.5 ) 9 . ECOG grade 0 2 10 . ASAT ALAT ≤ 2.5 N 11 . Bilirubin serum ≤ 2.5 N 12 . Women childbearing potential must use adequate method contraception 1 . Pregnant lactate woman , 2 . Participation another clinical trial investigative drug within 30 day prior study enrolment , 3 . Patient require antidiabetic medication 4 . Prior history hematopoietic stem cell transplantation ( autologous allogenic ) 5 . Cardiovascular disease : Stage II IV congestive heart failure ( CHF ) determine New York Heart Association ( NYHA ) classification system heart failure . Myocardial infarction within previous 6 month Symptomatic cardiac arrhythmia require treatment 6 . Grade III IV fluid retention 7 . Known BCRABL kinase domain mutation 8 . CML patient chronic phase diagnosis 9 . Individuals active malignancy 10 . Kown HIVpositivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>